

# Randomised Controlled Trial of CID versus CD for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma and Randomised Controlled Assessment of Interferon as Maintenance Treatment after Remission Induction

<b>Submission date</b> 19/08/2002	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 19/08/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 30/11/2015	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr - -

**Contact details**  
UKCCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

**Protocol serial number**  
SNLG NHLVIII

# Study information

## Scientific Title

Randomised Controlled Trial of CID versus CD for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma and Randomised Controlled Assessment of Interferon as Maintenance Treatment after Remission Induction

## Study objectives

Not provided at time of registration

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Study type(s)

Not Specified

## Health condition(s) or problem(s) studied

Lymphoma (non-Hodgkin's)

## Interventions

### INDUCTION / CONSOLIDATION:

Patients are randomised to one of two treatment arms:

1. Arm A: Chemotherapy with Chlorambucil, idarubicin and dexamethasone (CID), cycle to be repeated every 21 days. Patients showing a response following three courses will receive three further consolidation courses.
2. Arm B: Chemotherapy with Chlorambucil and dexamethasone (CD), cycle to be repeated every 21 days. Patients showing a response following three courses will receive three further consolidation courses.

**RADIOTHERAPY:** Patients may be given localised radiotherapy to initial areas of bulky disease if a complete response in that particular site has not been obtained following induction.

**MAINTENANCE:** Patients who have shown a complete response or good partial response following six cycles of induction therapy are eligible for the second randomisation. Patients are randomised to one of three groups:

1. Group A: No further therapy.
2. Group B: Low dose interferon, 1MU subcutaneously three times a week until progression or maximum of 36 months.
3. Group C: High dose interferon, 3MU subcutaneously three times a week until progression or maximum of 36 months.

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Not provided at time of registration

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

30/06/2000

**Eligibility****Key inclusion criteria**

1. Kiel classification of low grade non-Hodgkin's lymphoma
2. Stages II to IV
3. Age 15 to 70 years
4. Measurable disease
5. No prior chemotherapy
6. No central nervous system (CNS) involvement
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
8. Adequate bone marrow, renal and hepatic function
9. No medical contraindications to protocol treatments

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

Not Specified

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/01/1995

**Date of final enrolment**

30/06/2000

**Locations**

## Countries of recruitment

United Kingdom

England

## Study participating centre

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

## Sponsor information

### Organisation

Scotland & Newcastle Lymphoma Group (UK)

## Funder(s)

### Funder type

Research organisation

### Funder Name

Scottish & Newcastle Lymphoma Group (UK)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/11/2006		Yes	No